Pharmacoepidemiol Risk Manage.
2023 Sep;15(2):128-136. 10.56142/perm.23.0010.
Analysis of Treatment-Related Adverse Events in Hospitalized Patients with Coronavirus Disease 2019
- Affiliations
-
- 1Department of Health Administration, Cheju Halla University, Jeju, Korea
- 2Department of Preventive Medicine, Ulsan University Hospital, Ulsan, Korea
- 3Drug Safety Center, Seoul National University Hospital, Seoul, Korea
- 4Ulsan Center for Infectious Disease Control & Prevention, Ulsan, Korea
- 5College of Pharmacy and Institute of Pharmaceutical Sciences, CHA University, Pocheon, Korea
- 6College of Pharmacy, Seoul National University, Seoul, Korea
- 7Division of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea
- KMID: 2551229
- DOI: http://doi.org/10.56142/perm.23.0010
Abstract
Objective
This study aimed to assess the status and characteristics of adverse events caused by treatments of coronavirus disease 2019 (COVID-19) in hospitalized patients in Korea.
Methods
The medical records of patients hospitalized with COVID-19 at 30 medical institutions nationwide from January 1, 2020 to November 30, 2021 were retrospectively reviewed. Data of clinical characteristics; type of COVID-19 treatments; symptoms and severity of adverse events according to CTCAE classification; and prognosis of each patient were analyzed and presented descriptively.
Results
Adverse events were observed in 853 of 5,740 (14.9%) hospitalized patients with COVID-19: 732 (85.8%), mild; 106 (12.4%), moderate; and 15 (1.8%), severe. Serious adverse events were observed in 70 (1.2%) patients, with 56 prolonged hospitalizations and four deaths. Adverse events were more frequently found in patients with a lower-than-normal body mass index or many concomitant medications. Moreover, 4,912 patients (85.6%) received multiple medications for treatment of COVID-19, wherein the drugs most mainly administered were steroids (66.4%), antibiotics (59.5%), and remdesivir (52.6%). Adverse events were relatively common in patients administered immunoglobulin, other antiviral drugs, and interleukin-6 inhibitors. Each patient with adverse events had an average of 3.8 symptoms. The most frequent symptoms were increased hyperbilirubinemia (n = 256), nausea (n = 216), and pruritis (n = 188).
Conclusion
The incidence of adverse events in hospitalized patients with COVID-19 in Korea was approximately 14.9%. The type of treatment of COVID-19 might affect the incidence and prognosis of specific adverse events. Clinicians should consider the possible adverse effects of each medication before initiating treatment.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study
- Adverse events following vaccination against coronavirus disease 2019
- Coronavirus disease 2019 vaccines and relevant adverse reactions
- Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System
- COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021
